Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
When planning a moderately hypofractionationed treatment for prostate cancer, do you recommend using a bladder volume dose constraint?
For example V70<10cc? Or do you stick with % of organ volume dose constraints?
Answer from: Radiation Oncologist at Community Practice
We aim for 70 Gy < 10 and 35 Gy < 40 - 50 and try to avoid hot spot in bladder trigone region.
Comments
Radiation Oncologist at CCare
I noticed 70Gy <10cc and the lower V40 constrai...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
We do treat all with hypofractionation.
6198
6199
Sign in or Register to read more
10419
Related Questions
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
What are your top takeaways in GU Cancers from ASCO 2025?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
How would you manage a medically inoperable patient with locally recurrent nest variant muscle invasive urothelial carcinoma s/p radical cystectomy years ago now involving the urethral anastomosis, sphincter and neo-bladder, status post TUR?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
When do you start ADT for a patient with a new diagnosis of node positive prostate cancer receiving radiation?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
How do you manage prostate cancer in patients that cannot swallow pills?
I noticed 70Gy <10cc and the lower V40 constrai...
We do treat all with hypofractionation.